{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:24:51Z","timestamp":1782797091625,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,28]]},"DOI":"10.7759\/cureus.55178","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T03:04:42Z","timestamp":1709175882000},"source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Oral and IV Levonadifloxacin Therapy in Management of Bacterial Infections: Findings of a Prospective, Observational, Multi-center, Post-marketing Surveillance Study"],"prefix":"10.7759","author":[{"given":"Sanjith","family":"Saseedharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Zirpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatin","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Sutar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khokan","family":"Debnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket","family":"Newale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01138.x","article-title":"Current and emerging serious gram-positive infections","volume":"11","author":"Menichetti F","year":"2005","unstructured":"Menichetti F. Current and emerging serious gram-positive infections. Clin Microbiol Infect. 2005, 11:22-8. 10.1111\/j.1469-0691.2005.01138.x","journal-title":"Clin Microbiol Infect"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw828","article-title":"Gram-positive bacterial infections: research priorities, accomplishments, and future directions of the antibacterial resistance leadership group","volume":"64","author":"Doernberg SB","year":"2017","unstructured":"Doernberg SB, Lodise TP, Thaden JT, et al.. Gram-positive bacterial infections: research priorities, accomplishments, and future directions of the antibacterial resistance leadership group. Clin Infect Dis. 2017, 64:S24-9. 10.1093\/cid\/ciw828","journal-title":"Clin Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S176517","article-title":"Is methicillin-resistant Staphylococcus Aureus infection associated with higher mortality and morbidity in hospitalized patients? A cohort study of 551 patients from South Western India","volume":"11","author":"Chatterjee A","year":"2018","unstructured":"Chatterjee A, Rai S, Guddattu V, Mukhopadhyay C, Saravu K. Is methicillin-resistant Staphylococcus Aureus infection associated with higher mortality and morbidity in hospitalized patients? A cohort study of 551 patients from South Western India. Risk Manag Healthc Policy. 2018, 11:243-50. 10.2147\/RMHP.S176517","journal-title":"Risk Manag Healthc Policy"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1801-3","article-title":"Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment","volume":"21","author":"Hassoun A","year":"2017","unstructured":"Hassoun A, Linden PK, Friedman B. Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment. Crit Care. 2017, 21:211. 10.1186\/s13054-017-1801-3","journal-title":"Crit Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001974","article-title":"Antibiotic resistance in India: drivers and opportunities for action","volume":"13","author":"Laxminarayan R","year":"2016","unstructured":"Laxminarayan R, Chaudhury RR. Antibiotic resistance in India: drivers and opportunities for action. PLoS Med. 2016, 13:e1001974. 10.1371\/journal.pmed.1001974","journal-title":"PLoS Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/ijmm.IJMM_16_427","article-title":"Prevalence and genetic mechanisms of antimicrobial resistance in Staphylococcus species: A multicentre report of the indian council of medical research antimicrobial resistance surveillance network","volume":"35","author":"Rajkumar S","year":"2017","unstructured":"Rajkumar S, Sistla S, Manoharan M, et al.. Prevalence and genetic mechanisms of antimicrobial resistance in Staphylococcus species: A multicentre report of the indian council of medical research antimicrobial resistance surveillance network. Indian J Med Microbiol. 2017, 35:53-60. 10.4103\/ijmm.IJMM_16_427","journal-title":"Indian J Med Microbiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S229882","article-title":"Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: review of current evidence","volume":"13","author":"Bhagwat SS","year":"2019","unstructured":"Bhagwat SS, Nandanwar M, Kansagara A, et al.. Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: review of current evidence. Drug Des Devel Ther. 2019, 13:4351-65. 10.2147\/DDDT.S229882","journal-title":"Drug Des Devel Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2012.00043","article-title":"Intracellular Staphylococcus aureus: live-in and let die","volume":"2","author":"Fraunholz M","year":"2012","unstructured":"Fraunholz M, Sinha B. Intracellular Staphylococcus aureus: live-in and let die. Front Cell Infect Microbiol. 2012, 2:43. 10.3389\/fcimb.2012.00043","journal-title":"Front Cell Infect Microbiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1178633720970569","article-title":"A systemic literature review and meta-analysis reporting the prevalence and impact of methicillin-resistant Staphylococcus aureus infection in India","volume":"13","author":"Ghia CJ","year":"2020","unstructured":"Ghia CJ, Waghela S, Rambhad G. A systemic literature review and meta-analysis reporting the prevalence and impact of methicillin-resistant Staphylococcus aureus infection in India. Infect Dis. 2020, 13:1-16. 10.1177\/1178633720970569","journal-title":"Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/ijmm.IJMM_20_34","article-title":"A comparative assessment of clinical, pharmacological and antimicrobial profile of novel anti-methicillin-resistant Staphylococcus aureus agent levonadifloxacin: therapeutic role in nosocomial and community infections","volume":"37","author":"Bakthavatchalam YD","year":"2019","unstructured":"Bakthavatchalam YD, Rao SV, Isaac B, et al.. A comparative assessment of clinical, pharmacological and antimicrobial profile of novel anti-methicillin-resistant Staphylococcus aureus agent levonadifloxacin: therapeutic role in nosocomial and community infections. Indian J Med Microbiol. 2019, 37:478-87. 10.4103\/ijmm.IJMM_20_34","journal-title":"Indian J Med Microbiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001102","article-title":"Levonadifloxacin (WCK 771) exerts potent intracellular activity against Staphylococcus aureus in THP-1 monocytes at clinically relevant concentrations","volume":"68","author":"Dubois J","year":"2019","unstructured":"Dubois J, Dubois M. Levonadifloxacin (WCK 771) exerts potent intracellular activity against Staphylococcus aureus in THP-1 monocytes at clinically relevant concentrations. J Med Microbiol. 2019, 68:1716-22. 10.1099\/jmm.0.001102","journal-title":"J Med Microbiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire S","year":"2011","unstructured":"Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother. 2011, 55:649-58. 10.1128\/AAC.01201-10","journal-title":"Antimicrob Agents Chemother"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.841-851.2006","article-title":"Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages","volume":"50","author":"Barcia-Macay M","year":"2006","unstructured":"Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother. 2006, 50:841-51. 10.1128\/AAC.50.3.841-851.2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa142","article-title":"Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital","volume":"75","author":"Bakthavatchalam YD","year":"2020","unstructured":"Bakthavatchalam YD, Shankar A, Muniyasamy R, et al.. Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital. J Antimicrob Chemother. 2020, 75:2156-9. 10.1093\/jac\/dkaa142","journal-title":"J Antimicrob Chemother"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00641-06","article-title":"The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase","volume":"50","author":"Bhagwat SS","year":"2006","unstructured":"Bhagwat SS, Mundkur LA, Gupte SV, Patel MV, Khorakiwala HF. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. Antimicrob Agents Chemother. 2006, 50:3568-79. 10.1128\/AAC.00641-06","journal-title":"Antimicrob Agents Chemother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.3188-3192.2004","article-title":"Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents","volume":"48","author":"Peric M","year":"2004","unstructured":"Peric M, Jacobs MR, Appelbaum PC. Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents. Antimicrob Agents Chemother. 2004, 48:3188-92. 10.1128\/AAC.48.8.3188-3192.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/986938","article-title":"Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update","volume":"2014","author":"Villafuerte-Gutierrez P","year":"2014","unstructured":"Villafuerte-Gutierrez P, Villalon L, Losa JE, Henriquez-Camacho C. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. Adv Hematol. 2014, 2014:986938. 10.1155\/2014\/986938","journal-title":"Adv Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq196","article-title":"Management of febrile neutropenia: ESMO Clinical Practice Guidelines","volume":"21","author":"de Naurois J","year":"2010","unstructured":"de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2010, 21:v252-6. 10.1093\/annonc\/mdq196","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline update","volume":"36","author":"Taplitz RA","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, et al.. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline update. J Clin Oncol. 2018, 36:3043-54. 10.1200\/JCO.18.00374","journal-title":"J Clin Oncol"},{"key":"ref20","article-title":"Efficacy and safety of a novel broad-spectrum anti-MRSA agent levonadifloxacin compared with linezolid for acute bacterial skin and skin structure infections: a phase 3, openlabel, randomized study","volume":"68","author":"Bhatia A","year":"2020","unstructured":"Bhatia A, Mastim M, Shah M, et al.. Efficacy and safety of a novel broad-spectrum anti-MRSA agent levonadifloxacin compared with linezolid for acute bacterial skin and skin structure infections: a phase 3, openlabel, randomized study. J Assoc Physicians India. 2020, 68:30-6.","journal-title":"J Assoc Physicians India"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1159\/000334441","article-title":"QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications","volume":"120","author":"Briasoulis A","year":"2011","unstructured":"Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology. 2011, 120:103-10. 10.1159\/000334441","journal-title":"Cardiology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12594","article-title":"Electrocardiographic effects of a supratherapeutic dose of WCK 2349, a benzoquinolizine \ufb02uoroquinolone","volume":"12","author":"Mason JW","year":"2019","unstructured":"Mason JW, Chugh R, Patel A, Gutte R, Bhatia A. Electrocardiographic effects of a supratherapeutic dose of WCK 2349, a benzoquinolizine \ufb02uoroquinolone. Clin Transl Sci. 2019, 12:47-52. 10.1111\/cts.12594","journal-title":"Clin Transl Sci"},{"key":"ref23","article-title":"Electrocardiographic effects of WCK 2349","author":"Mason JW","year":"2016","unstructured":"Mason JW, Chugh R, Lakdavala F, Bhatia A. Electrocardiographic effects of WCK 2349. 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9th-12th. 2016, 1269.","journal-title":"26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9th-12th"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/191242-efficacy-and-safety-of-oral-and-iv-levonadifloxacin-therapy-in-management-of-bacterial-infections-findings-of-a-prospective-observational-multi-center-post-marketing-surveillance-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T03:04:46Z","timestamp":1709175886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/191242-efficacy-and-safety-of-oral-and-iv-levonadifloxacin-therapy-in-management-of-bacterial-infections-findings-of-a-prospective-observational-multi-center-post-marketing-surveillance-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.55178","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,28]]}}}